Sei Investments Co. lessened its holdings in shares of Sanofi (NYSE:SNY) by 2.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 595,151 shares of the company’s stock after selling 15,268 shares during the quarter. Sei Investments Co.’s holdings in Sanofi were worth $29,633,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Parallel Advisors LLC grew its stake in Sanofi by 42.5% during the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after purchasing an additional 875 shares in the last quarter. YorkBridge Wealth Partners LLC grew its stake in Sanofi by 33.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after purchasing an additional 776 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in Sanofi by 142.8% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after purchasing an additional 2,098 shares in the last quarter. Toronto Dominion Bank grew its stake in Sanofi by 4.6% during the 2nd quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock valued at $195,000 after purchasing an additional 180 shares in the last quarter. Finally, River Road Asset Management LLC acquired a new stake in Sanofi during the 3rd quarter valued at approximately $208,000. Hedge funds and other institutional investors own 9.36% of the company’s stock.
SNY has been the subject of several research reports. Argus reiterated a “buy” rating and issued a $55.00 target price on shares of Sanofi in a research report on Friday, September 1st. Zacks Investment Research lowered Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. HSBC Holdings plc upgraded Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. BidaskClub lowered Sanofi from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $53.50.
In related news, major shareholder Sanofi acquired 105,820 shares of Sanofi stock in a transaction that occurred on Thursday, August 24th. The stock was acquired at an average price of $482.04 per share, for a total transaction of $51,009,472.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 1.00% of the company’s stock.
Sanofi (NYSE SNY) traded down $0.42 during trading hours on Friday, reaching $45.00. The company had a trading volume of 1,525,500 shares, compared to its average volume of 1,393,183. Sanofi has a twelve month low of $38.45 and a twelve month high of $50.65. The firm has a market cap of $113,467.86, a price-to-earnings ratio of 14.20, a P/E/G ratio of 2.48 and a beta of 0.88. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.